As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.
The FDA has granted fast-track approval for a groundbreaking gene therapy indicated for a rare genetic disorder called aromatic L-amino acid decarboxylase (AADC) deficiency.
Hello, Reader. For all that artificial intelligence has accomplished over the last few years, one thing it has not yet ...
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...
The FDA's REMS program has been found to have unintentionally created barriers to accessing clozapine, a crucial ...
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, 2024, compared to a net loss of approximately $11.3 million, or $0.48 per ...
The Company currently has 12 listed patents for IGALMI in the FDA’s Approved Drug Products with Therapeutic Equivalence ... of agitation associated with bipolar I or II disorder or schizophrenia in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback